Ratings Lotus Pharmaceutical Co., Ltd. Taipei Exchange

Equities

1795

TW0001795003

End-of-day quote Taipei Exchange Other stock markets 04:30:00 13/12/2019 am IST			5-day change	1st Jan Change
108 ^TWD	+0.47%		-4.42%	-.--%

11/05	Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
26/03	Lotus Pharmaceutical Co., Ltd. Announces Change in Representative of the Company's Institutional Director	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

The company's enterprise value to sales, at 4.45 times its current sales, is high.
The company appears highly valued given the size of its balance sheet.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
LOTUS PHARMACEUTICAL CO., LTD.	-.--%	2.39B	-
ELI LILLY AND COMPANY	+34.35%	705B	C+
NOVO NORDISK A/S	+29.39%	583B	B
JOHNSON & JOHNSON	-3.49%	364B	C+
MERCK & CO., INC.	+20.15%	332B	B-
ABBVIE INC.	+6.19%	291B	C+
ASTRAZENECA PLC	+14.11%	238B	B+
ROCHE HOLDING AG	-3.03%	210B	A+
NOVARTIS AG	+10.02%	209B	B-
AMGEN INC.	+9.21%	169B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes